» Articles » PMID: 11398806

Immunologic Approach to Herpes Simplex Virus

Overview
Journal Viral Immunol
Date 2001 Jun 12
PMID 11398806
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The fundamental biological characteristic of herpes simplex virus (HSV) infection is its ability to establish latency and periodically reactivate, resulting in productive infectious virus. Recurrent HSV infections occur in spite of the presence of host immune responses to the virus. Because genital herpes is currently one of the three most prevalent sexually transmitted diseases worldwide, its potential public health impact has contributed to increased awareness in medical communities. The current state of knowledge on the immunological control of primary and recurrent HSV infections is reviewed, as well as the various immune-based therapeutic approaches to resultant disease. Finally, the potential benefit of immune response modifiers (IRMs), which have shown promise in early clinical studies, is discussed.

Citing Articles

Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa.

Dhanushkodi N, Prakash S, Quadiri A, Zayou L, Srivastava R, Tran J J Immunol. 2023; 211(1):118-129.

PMID: 37222480 PMC: 10330291. DOI: 10.4049/jimmunol.2300093.


Herpes Simplex Virus Type-2 Paralyzes the Function of Monocyte-Derived Dendritic Cells.

Grosche L, Muhl-Zurbes P, Ciblis B, Krawczyk A, Kuhnt C, Kamm L Viruses. 2020; 12(1).

PMID: 31963276 PMC: 7019625. DOI: 10.3390/v12010112.


Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Dervillez X, Gottimukkala C, Kabbara K, Nguyen C, Badakhshan T, Kim S Future Virol. 2012; 7(4):371-378.

PMID: 22701511 PMC: 3372919. DOI: 10.2217/fvl.12.22.


Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Dasgupta G, Chentoufi A, Kalantari M, Falatoonzadeh P, Chun S, Lim C J Virol. 2012; 86(8):4358-69.

PMID: 22318137 PMC: 3318627. DOI: 10.1128/JVI.07107-11.


Developing an asymptomatic mucosal herpes vaccine: the present and the future.

Dasgupta G, Nesburn A, Wechsler S, BenMohamed L Future Microbiol. 2009; 5(1):1-4.

PMID: 20020824 PMC: 4512283. DOI: 10.2217/fmb.09.101.